Parallel session: HBV cure: Pre-clinical studies

 Viral hepatitis

South 4
12 April 2018 16:00 - 18:00


PS-025 Combinatorial RNAi/vaccination therapy for chronic hepatitis B achieves long-term functional cure in preclinical mouse model
Thomas Michler , Germany
12 April 2018 16:00 - 16:15

PS-026 Novel and potent HBV capsid modulator reduces HBeAg and cccDNA in core site directed T109I mutant in HepNTCP cells
Leda Bassit , United States
12 April 2018 16:15 - 16:30

PS-027 Preclinical antiviral drug combination studies utilizing novel orally bioavailable investigational agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, a HBV RNA destabilizer
Nagraj Mani , United States
12 April 2018 16:30 - 16:45

PS-028 Combination treatment of a TLR7 agonist RO7020531and a capsid assembly modulator RO7049389 achieved sustainable viral loadsuppression and HBsAg loss in an AAV-HBV mouse model
Lu Gao , China
12 April 2018 16:45 - 17:00

PS-029 Durable inhibition of hepatitis B virus replication and antigenemia using a subcutaneously administered siRNA agent in preclinical models
Amy C.H. Lee , Canada
12 April 2018 17:00 - 17:15

PS-030 Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection
Christine Wooddell , United States
12 April 2018 17:15 - 17:30

PS-031 T cells grafted with HBV-specific T-cell receptors of high functional avidity achieve functional cure of HBV infection in humanized mice
Ulrike Protzer , Germany
12 April 2018 17:30 - 17:45

PS-032 Discovery of a novel HBV core inhibitor EP-027367 with potent antiviral activity both in vitro and in a humanized mouse model
Michael Vaine , United States
12 April 2018 17:45 - 18:00